Your Session will expire soon
As you have been inactive for nearly 15 minutes you will soon be logged out of the secure area of our website. Click OK to remain logged in.
020 7189 9999
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies.
| Sector | Specialist | |
|---|---|---|
| Structure | OFFSHORE FUND | |
| Launched | April, 2009 | |
| Size | £1m | |
| Yield | 0.0% | |
| Charging basis | – | |
| Dividends paid | – | |
| Standard initial charge | 5.00% |
|---|---|
| Initial charge via Bestinvest | 0.00% |
| Additional bid/offer spread | 0.00% |
| Annual management charge | 1.50% |
| Ongoing charges figure | 1.50% |
Before investing make sure you have understood the risks relevant to the fund by reviewing our Risk Warnings section. Further information on the risks are contained in the fund's Key Investor Information Document, which we make available to you before you make a decision to invest, alternatively it is available on request.
No information available.
| Allocation | Proportion(%) | |
|---|---|---|
| Equity | 96 | |
| High yield bonds | 0 | |
| Quality bonds | 0 | |
| Property | 0 | |
| Commodities | 0 | |
| Hedge | 0 | |
| Fund cash | 4 | |
| Allocation | Proportion(%) | |
|---|---|---|
| UK | 7 | |
| Europe | 16 | |
| North America | 72 | |
| Japan | 2 | |
| Pacific | 0 | |
| Emerging Markets | 3 | |
| Allocation | Proportion(%) | |
|---|---|---|
| Large Caps | 48 | |
| Mid Caps | 25 | |
| Small Caps | 27 | |
No information available.
| Bid price(inc) | 2,936.00p |
|---|---|
| Accum units | 2,945.00p |
| Fund commentary | |
| Fund data updated on | 26/09/17 |
| Allocation | Proportion(%) | |
|---|---|---|
| Equity | 96 | |
| High yield bonds | 0 | |
| Quality bonds | 0 | |
| Property | 0 | |
| Commodities | 0 | |
| Hedge | 0 | |
| Fund cash | 4 | |
| Allocation | Proportion(%) | |
|---|---|---|
| UK | 7 | |
| Europe | 16 | |
| North America | 72 | |
| Japan | 2 | |
| Pacific | 0 | |
| Emerging Markets | 3 | |
| Allocation |
Propor tion(%) |
|
|---|---|---|
| Large Caps | 48 | |
| Mid Caps | 25 | |
| Small Caps | 27 | |
As at: 31/10/11
7.1% Johnson & Johnson
5.6% Roche Holding
5.5% Pfizer
5.4% Abbott Labs
4.1% Sanofi
3.1% Allergan
2.9% Celgene
2.6% Pharmasset
2.5% Amgen
2.5% Baxter International
Source: Polar Capital
No information available.
No information available.
| Average monthly relative returns | Bestinvest MRI | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/13 | 13/14 | 14/15 | 15/16 | 16/17 | 3 years | 5 years | Career | 3 years | 5 years | Career | |
| – | – | – | -0.07% | 0.35% | – | – | -0.24% | – | – | 38.20% | |
| Performance figures are based on the average of monthly percentage returns relative to the benchmark index. | |||||||||||
Powell and Mahony are portfolio Manager’s and co-head’s of the Manager's Healthcare Business unit at Polar Capital LLP. Powell has over 10 years' investment experience in the healthcare sector, with over 8 years as a portfolio Manager. He joined Polar Capital in 2007 and is currently co-manager of the Polar Healthcare Opportunities Fund.
Mahony has more than 11 years' investment experience in the healthcare sector, with over 2 years as a Portfolio Manager and 9 years as a sell-side analyst. Prior to joining Polar Capital, he was Head of the European Healthcare Research Team at Morgan Stanley, which covered the European Biotechnology, Medical.
Gareth Powell / Daniel Mahony has 2.7 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been -0.24%. During the worst period of relative performance (from May 2009 - May 2011) there was a decline of 14% relative to the index. The worst absolute loss has been 16%.
| Periods of worst performance | |
|---|---|
| Absolute | -16% (March 2010 - July 2010) |
| Relative | -14% (May 2009 - May 2011) |
Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.
As you have been inactive for nearly 15 minutes you will soon be logged out of the secure area of our website. Click OK to remain logged in.